Phase 3 clinical trial has been given approval by FDA
The FDA has given Ocugen permission to start their phase 3 gene therapy clinical trial for retinitis pigmentosa (RP).
Search
Search results
Could eye drops treat retinal disease in the future?
Researchers have developed PEDF-based eye drops that show promise in slowing retinal degeneration in mice with retinitis pigmentosa, potentially offering a non-invasive treatment option for preserving vision in the future.
Giving in memory
Celebrate the life of your loved one, by donating in their memory and help us fund more research and support, now.
Meet our Trustee: Rob Halliwell
Rob is a Chief Technology Officer based in Manchester, with over 20 years’ experience leading technology, software development and digital transformation.
Our manifesto
Retina UK are committed to improving the lives of people affected by inherited retinal dystrophies (IRDs).
Looking after your vision
It is important to avoid harming your vision, particularly if you have an inherited sight loss condition.
Podcast: Introducing our new chair
A new Retina UK podcast that introduces our new chair of trustees, Kathy Evans.
e-Newsletter October 2024
Our monthly e-Newsletter featuring the latest updates from Retina UK.
Volunteer Impact Report
Our volunteers are highly valued members of the Retina UK team and their roles are essential to help support and enable people affected by inherited sight loss to live fulfilling lives.
Webinar: The Big Give: How your donations make a difference
Join us to find out how your donations make a direct different and fund research.